share_log

Ionis, Ono Pharmaceutical Enter License Agreement; Ionis To Receive $280M Million Upfront Payment, With Potential To Earn Up To $660M In Milestones

Benzinga ·  Mar 11 22:04

Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease.

Ionis is also eligible to earn royalties in the mid-teen percentage range on annual net sales of sapablursen.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 321

Recommended

Write a comment